Axial Spondyloarthritis Market Size and Trends Analysis By DelveInsight
DelveInsight's "Axial Spondyloarthritis Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the disease, historical and forecasted epidemiology, the pipeline insight as well as the Axial Spondyloarthritis market size and shares analysis in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. The report also covers emerging drugs, current treatment practices, Axial Spondyloarthritis market shares of the individual therapies, a detailed current Axial Spondyloarthritis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the market.
Axial spondyloarthritis (axSpA) is an umbrella term for inflammatory arthritis type that primarily affects the spine and the sacroiliac (SI) joints that connect the lower spine to the pelvis, resulting in pain in the lower back, hips, and buttocks. There are two subtypes of axSpA: Non-radiographic axial spondyloarthritis (nr-axSpA) and Ankylosing spondylitis (AS).
Axial Spondyloarthritis Market Key Facts
- As per the Curtis et al. (n.d.), in the USA, the estimated prevalence of SpA is around 22.6/10,000.
- As per DelveInsight’s analysis, the prevalent cases of axial spondyloarthritis are higher in the US among the 7MM.
- It is observed that only a small proportion of patients classified as nr-axSpA progress to AS, at least in the short term.
Axial Spondyloarthritis Market Trends
Axial Spondyloarthritis market size is expected to increase during the forecast period owing to the increasing prevalent population of axSpA patients in the 7MM. Extensive research and development activities of pharmaceutical companies, along with the expected launch of approved therapies will also fuel the market growth.
The Axial Spondyloarthritis market analysis section of the report helps to understand the current and forecasted Axial Spondyloarthritis market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers. The report gives complete detail of Axial Spondyloarthritis market Size and Shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Axial Spondyloarthritis Epidemiology Forecast
The Axial Spondyloarthritis epidemiology section covers insights about historical and current Axial Spondyloarthritis patient pool and forecasted trends for every seven major countries (i.e., the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan. It helps to recognize the causes of current and forecasted Axial Spondyloarthritis Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
Axial Spondyloarthritis Epidemiology Segmentation
- Total Prevalent cases of Spondyloarthritis
- Total Prevalent cases of Axial Spondyloarthritis
- Age-specific cases of Axial Spondyloarthritis
- Type-specific cases of Axial Spondyloarthritis
Axial Spondyloarthritis Therapeutics Market
The treatment approaches to ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) are similar. Several treatments are available; the selection is tailored for each individual, based on the characteristics and severity. At present, several companies worldwide are persistently working towards the development of new treatment therapies that are expected to launch during the forecast period.
Some of the key companies in the Axial Spondyloarthritis Market includes AbbVie, UCB Biopharma SRL, Eli Lilly and Company, Kyowa Hakko Kirin, Galapagos NV., and others. Axial Spondyloarthritis Therapies covered in the report include Bimekizumab, Ixekizumab, Upadacitinib, Brodalumab, Filgotinib, and many more.
For more details, visit: Axial Spondyloarthritis Market Trends